Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 11/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008570 | 0.95 | KIF11 (0.52) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL18095444 | 0.88 | KIF11 (0.49) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL2821674 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL3190599 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL26176911 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL24207815 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL3485522 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL4454711 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL24207971 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 | |
| SCHEMBL26176881 | 0.87 | KIF11 (0.55) | KIF11HRH4TK2TK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | NANOGENICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | ITGB1, ITGA2B, ITGB2 | KIF11 2529/4885HRH4 3894/4885TK2 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.